Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimoto, Takayuki, Mizoguchi, Izuru, Katagiri, Seiichiro, Tauchi, Tetsuzo, Furusawa, Jun-ichi, Chiba, Yukino, Mizuguchi, Junichiro, Ohyashiki, Junko H, Ohyashiki, Kazuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091524/
https://www.ncbi.nlm.nih.gov/pubmed/25057448
http://dx.doi.org/10.4161/onci.28861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091524/
https://www.ncbi.nlm.nih.gov/pubmed/25057448
http://dx.doi.org/10.4161/onci.28861

Ejemplares similares